Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-27T22:40:27.581Z Has data issue: false hasContentIssue false
  • English
  • Français

Permax

Published online by Cambridge University Press:  18 September 2015

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 4 , November 1997 , pp. A-55
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

References:

1.Jankovic, J. Pergolide: Short-term and long-term experience in Parkinson’s disease. Recent Developments in Parkinson’s Disease, ed by Fahn, Set al. Raven Press, New York 1986Google Scholar
2.Jenner, P. The rationale for the use of dopamine agonists in Parkinson’s disease. Neurology 1995:45(suppl 3):S6-S12.CrossRefGoogle ScholarPubMed
3.Olanow, CWFahn, SMuenter, MKlawans, HHurtig, HStern, MShoulson, I. Kurlan, RGrimes, JOJankovic, Jet al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord (1994 Jan) 9(1):40–7.CrossRefGoogle ScholarPubMed
4.Goetz, CGet al. Chronic agonist therapy lor Parkinson’s disease: A 5-year study of bromocriptine and pergolide. Neurology (1985 May) 35(5)749–51.CrossRefGoogle Scholar
5.Mizuno, Yet al. Pergolide in the treatment ot Parkinson’s disease. Neurology 1995:45(suppl 3):S13-S21.CrossRefGoogle Scholar
6.Goetz, CGet al. Agonist substitution in advanced Parkinson’s disease. Neurology 1989;39:1121–1122.CrossRefGoogle ScholarPubMed